694 related articles for article (PubMed ID: 38429828)
1. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L; Lu Y; Liu W; Wang S; Wang L; Zheng P; Zi G; Liu H; Liu W; Wei S
Exp Hematol Oncol; 2024 Mar; 13(1):26. PubMed ID: 38429828
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
3. Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
Gogia P; Ashraf H; Bhasin S; Xu Y
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
[TBL] [Abstract][Full Text] [Related]
6. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
7. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
Barreca M; Lang N; Tarantelli C; Spriano F; Barraja P; Bertoni F
Explor Target Antitumor Ther; 2022; 3(6):763-794. PubMed ID: 36654819
[TBL] [Abstract][Full Text] [Related]
9. Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.
Wu M; Huang W; Yang N; Liu Y
Exp Hematol Oncol; 2022 Nov; 11(1):93. PubMed ID: 36348391
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs.
Zhang J; Hu F; Aras O; Chai Y; An F
ChemMedChem; 2024 Jun; 19(11):e202300720. PubMed ID: 38396351
[TBL] [Abstract][Full Text] [Related]
11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
12. Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
Sau S; Alsaab HO; Kashaw SK; Tatiparti K; Iyer AK
Drug Discov Today; 2017 Oct; 22(10):1547-1556. PubMed ID: 28627385
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
Takakura T; Shimizu T; Yamamoto N
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38704241
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ; Luo S; Twomey JD; Zhang B
MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
17. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.
Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł
Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer.
Manzano A; Ocaña A
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784819
[TBL] [Abstract][Full Text] [Related]
19. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
20. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
